Efficacy and safety of maropitant, a selective neurokinin 1 receptor antagonist, in two randomized clinical trials for prevention of vomiting due to motion sickness in dogs.

MLA

Conder, G. A., et al. “Efficacy and Safety of Maropitant, a Selective Neurokinin 1 Receptor Antagonist, in Two Randomized Clinical Trials for Prevention of Vomiting Due to Motion Sickness in Dogs.” Journal of Veterinary Pharmacology and Therapeutics, vol. 31, no. 6, Dec. 2008, pp. 528–32. EBSCOhost, https://doi.org/10.1111/j.1365-2885.2008.00990.x.

APA

Conder, G. A., Sedlacek, H. S., Boucher, J. F., & Clemence, R. G. (2008). Efficacy and safety of maropitant, a selective neurokinin 1 receptor antagonist, in two randomized clinical trials for prevention of vomiting due to motion sickness in dogs. Journal of Veterinary Pharmacology and Therapeutics, 31(6), 528–532. https://doi.org/10.1111/j.1365-2885.2008.00990.x

Chicago

Conder, G A, H S Sedlacek, J F Boucher, and R G Clemence. 2008. “Efficacy and Safety of Maropitant, a Selective Neurokinin 1 Receptor Antagonist, in Two Randomized Clinical Trials for Prevention of Vomiting Due to Motion Sickness in Dogs.” Journal of Veterinary Pharmacology and Therapeutics 31 (6): 528–32. doi:10.1111/j.1365-2885.2008.00990.x.